Seeking Alpha

Shares of Halozyme Therapeutics (HALO) fall 23.1% premarket before tripping up circuit breakers....

Shares of Halozyme Therapeutics (HALO) fall 23.1% premarket before tripping up circuit breakers. All the fuss is over an announcement from the company that says the FDA requested more information on its HyQ Biologics Application before it can complete its review.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs